GLOPID-R

IMI – EU

The Innovative Medicines Initiative (IMI), a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) has launched a Call for proposals on COVID-19.

Scope

The scope of this fast-track call, with a budget of €45 million, remains broad and focuses on the development of:

  • therapeutics to address the current COVID-19 outbreak and/or future coronavirus outbreaks
  • development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies
  • development of fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection.

Preventive vaccines are specifically excluded from the scope of the Call.

Read the full request for proposal

  • Call budget: €45 M
  • Call opens: March 03, 2020
  • Application deadline: March 31, 2020
EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874667.